BRAINTREE, Mass.--(BUSINESS WIRE)--Paragonix Technologies, Inc., announced today that it has entered into an exclusive distribution agreement with MBA Medical to market Paragonix Technologies’ SherpaPak™ Cardiac and Kidney Transport Systems, innovative static hypothermic preservation and transport devices for donor organs, in leading transplant centers in the Southern United States.
“Innovative Cold Storage Of Donor Organs Using The Paragonix SherpaPak™ Devices”
William Edelman, Chairman & CEO of Paragonix Technologies, commented, “We are excited for MBA Medical to join our expanding SherpaPak™ distributor network, which now covers the Pacific Region, the Midwest, and the Southern United States. Following exciting feedback on SherpaPak™ Cardiac and Kidney Transport Systems from the transplant community, we are delighted for MBA Medical to join our distributor network to supply SherpaPak™ to the transplant community in Texas, Mississippi, Missouri and Alabama.” Mr. Edelman continued, “SherpaPak™ provides best-in-class donor organ management solutions for safe and reliable preservation and transport of donor hearts and kidneys. The Paragonix SherpaPak™ devices for kidney and heart preservation are an important step in improving donor organ transportation. We believe that improving the utilization of donated organs is critical to patients in end-stage organ failure who are desperate for this precious commodity.”
Previous Announcements
Paragonix previously announced January 4 2017, an Exclusive Supply Agreement with Sanbor Medical for the Manufacture and Assembly of SherpaPak™ Organ Transport Systems
Paragonix previously announced December 22, 2016 an Exclusive Distribution agreement with Bio Instruments for Paragonix SherpaPak™ Cardiac and Kidney Transport Systems in the Midwestern United States
Paragonix previously announced November 9, 2016 an Exclusive Distribution Agreement with Pacific West Medical Sales for Paragonix SherpaPak™ Cardiac and Kidney Transport Systems in California
Paragonix previously announced June 29, 2016 a Product Supply Agreement with Waters Medical Systems LLC, Announce for Waters IGL and Celsior® Cold Storage Solutions for Use With the SherpaPak™ Kidney Transport System and SherpaPak™ Cardiac Transport System
Paragonix and Essential Pharmaceuticals LLC previously announced June 28, 2016, a Product Supply Agreement for Custodiol® HTK Organ Preservation Solution for Use With the SherpaPak™ Cardiac Transport System and SherpaPak™ Kidney Transport System
Paragonix previously announced June 6, 2016, Presentation of the SherpaPak™ Cardiac Transport System during the 2016 American Transplant Congress June 11 - 15, 2016 in Boston, MA
Paragonix previously announced on July 23, 2015, Publication of “Innovative Cold Storage Of Donor Organs Using The Paragonix SherpaPak™ Devices"1
Paragonix previously announced on February 9, 2015, Innovative Tracking Technology For Real-Time, National Location Tracking of Donor Organs
About MBA Medical
MBA Medical has been supplying specialty
medical products to hospital facilities in Texas, Louisana, Alabama and
Mississippi for over 15 years.
About the Paragonix SherpaPak™ Cardiac and Kidney Transport System
Paragonix
SherpaPak™ Cardiac and Kidney Transport Systems are
single-use, fully disposable organ transport devices. SherpaPak™ maintains
organ storage temperature between 4-8°C during the organ preservation
interval and precisely monitors preservation temperature. SherpaPak™
consists of a shipper with an integrated datalogger, cooling
pouches, and two nesting sterile canisters with a temperature probe
measuring organ preservation solution temperature.
About Paragonix Technologies, Inc.
Based in Massachusetts
and founded in 2010, Paragonix Technologies Inc., is a privately held
medical device company innovating the Paragonix SherpaPak™ and
SherpaPerfusion™ Cardiac Transport System, a novel, single-use organ
preservation device to improve donor organ quality. Paragonix has
established a pipeline of donor organ transport devices that address the
current donor organ shortage by maximizing donor organ utilization,
improving donor organ quality and extending donor organ transport
throughout the entire United States. Paragonix has developed Sherpa
devices both for static hypothermic storage as well as oxygenated
hypothermic perfusion.
1 Michel et al. Heart, Lung and Vessels; 2015;7(3):246-55
Paragonix Technologies Inc.
Bill Edelman, 781-436-0509 o/c
bill@paragonixtechnologies.com
www.paragonixtechnologies.com